Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may
be associated with aggressive disease and poorer outcomes, and can have hereditary …

Purpose Advances in germline genetics, and related therapeutic opportunities, present new
opportunities and challenges in prostate cancer. The Prostate Cancer Clinical Trials …

Simple Summary Advances in our understanding of the molecular basis of prostate cancer
have resulted in the discovery of a subset of patients harboring germline variants that places …

Purpose We describe the pathogenic variant spectrum and identify predictors of positive
results among men referred for clinical genetic testing for prostate cancer. Methods One …

Context Germline testing (GT) is increasingly impacting prostate cancer (PCa) management
and screening, with direct effects in urology, medical oncology, and radiation oncology. The …

Recent advances clearly demonstrate the potential clinical relevance of germline genetic
testing and somatic genomic profiling in identifying possible therapeutic and/or clinical trial …

Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of
prostate cancer, in particular cases with metastatic disease are selected. Advances in the …

It is increasingly important for clinicians involved in the management of prostate cancer to
understand the relevance of heritable (germline) mutations that, for select patients, affect …

Prostate cancer (PCa) remains the most common cancer in men. The proportion of all PCa
attributable to high-risk hereditary factors has been estimated to 5–15%. Recent landmark …